The SweetMeds Study: Sucralose and Drug Absorption
This study, called The SweetMeds Study, is looking at how sucralose, a common artificial sweetener, affects how your body absorbs and uses certain medications. Specifically, it will examine its effects on digoxin and midazolam, which are examples of drugs that use specific pathways in the body. Researchers also want to see if sucralose changes hormone levels, gut bacteria, and fat cells. You might be able to join if you are a woman between 18 and 60 years old, identify as Hispanic and/or Black, weigh over 110 pounds, and have a body mass index (BMI) between 25 and 40. The study aims to enroll 150 participants. The current status of this study is unclear.
- Study design
- This is an interventional study, meaning participants will receive either sucralose or a placebo (an inactive substance). The study plans to enroll 150 participants.
- What's involved
- You would take sucralose or placebo capsules by mouth for 28 days. You would also answer questions, provide daily urine samples, and one stool sample over 7 days. You must not eat or drink anything with artificial sweeteners throughout the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary effects of sucralose on drug processing will be measured at 28 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
At a glance
Conditions
NCT03407079
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
National Institutes of Health Clinical Center
Bethesda, Marylandstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Paule V Joseph, C.R.N.P. · PRINCIPAL_INVESTIGATOR · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To explore the effects of sucralose (approx 4 mg/kg x 28 days) on pharmacokinetics of digoxin and midazolam, which are representative examples of P-gp and CYP3A dependent medications.28 days
To determine the effects of sucralose (4 mg/kg/day) administered to overweight and obese minority women for 28 days on drug metabolism using digoxin and midazolam as probes for P-glycoprotein and CYP3A, respectively.